These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 30917722)

  • 1. Lansoprazole-Induced Thrombocytopenia in a Critically Ill Patient: A Case Report.
    Saad M; Mitwally H
    J Pharm Pract; 2020 Oct; 33(5):700-704. PubMed ID: 30917722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pantoprazole-induced Thrombocytopenia: Unresponsive to Corticosteroid and Thrombocyte Concentrate Transfusion.
    Widyati ; Latifah N; Ramadhani M
    J Pharm Pract; 2023 Jun; 36(3):711-715. PubMed ID: 34965162
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lansoprazole-induced thrombocytopenia.
    Zlabek JA; Anderson CG
    Ann Pharmacother; 2002 May; 36(5):809-11. PubMed ID: 11978156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump induced thrombocytopenia: A case report and review of literature.
    Kallam A; Singla A; Silberstein P
    Platelets; 2015; 26(6):598-601. PubMed ID: 25207666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pantoprazole-induced thrombocytopenia.
    Watson TD; Stark JE; Vesta KS
    Ann Pharmacother; 2006 Apr; 40(4):758-61. PubMed ID: 16569810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
    Falhammar H; Lindh JD; Calissendorff J; Skov J; Nathanson D; Mannheimer B
    Eur J Intern Med; 2019 Jan; 59():65-69. PubMed ID: 30154038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
    Pilotto A; Franceschi M; Leandro G; Scarcelli C; D'Ambrosio LP; Paris F; Annese V; Seripa D; Andriulli A; Di Mario F
    World J Gastroenterol; 2007 Sep; 13(33):4467-72. PubMed ID: 17724802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding.
    Binnetoğlu E; Akbal E; Şen H; Güneş F; Erbağ G; Aşık M; Bozkurt N; Uludağ A; Tekin M; Tekin SZ
    Platelets; 2015; 26(1):10-2. PubMed ID: 24512269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
    Clark DW; Strandell J
    Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.
    Mulder CJ; Westerveld BD; Smit JM; Oudkerk Pool M; Otten MH; Tan TG; van Milligen de Wit AW; de Groot GH;
    Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):649-56. PubMed ID: 12072599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
    Martin RM; Dunn NR; Freemantle S; Shakir S
    Br J Clin Pharmacol; 2000 Oct; 50(4):366-72. PubMed ID: 11012560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro.
    Escoffier J; Arnaud B; Kaba M; Hograindleur JP; Le Blévec E; Martinez G; Stévant I; Ray PF; Arnoult C; Nef S
    Andrology; 2020 Nov; 8(6):1795-1804. PubMed ID: 32609951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereoselective disposition of proton pump inhibitors.
    Andersson T; Weidolf L
    Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
    Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
    Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori.
    Nakao M; Malfertheiner P
    Helicobacter; 1998 Mar; 3(1):21-7. PubMed ID: 9546114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
    Thomson AB
    Curr Gastroenterol Rep; 2000 Dec; 2(6):482-93. PubMed ID: 11079051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.